(R)-5-cyclopentyl-4-ethyl-N-(4-morpholinophenyl)-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-amine | 954417-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (R)-5-cyclopentyl-4-ethyl-N-(4-morpholinophenyl)-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-amine
• 英文别名: (4R)-5-cyclopentyl-4-ethyl-N-(4-morpholin-4-ylphenyl)-4H-[1,2,4]triazolo[4,3-f]pteridin-7-amine
• CAS: 954417-39-1
• 化学式: C₂₄H₃₀N₈O
• 分子量: 446.555
• InChiKey: FDEPNWBFKSMMND-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Tetrahydropteridines useful as inhibitors of protein kinases
  申请人：Charrier Jean-Damien

  公开号：US20090062292A1

  公开（公告）日：2009-03-05

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及作为蛋白激酶抑制剂有用的化合物。该发明还提供包括所述化合物的药学上可接受的组合物，以及在治疗各种疾病、症状或紊乱中使用这些组合物的方法。该发明还提供制备本发明化合物的方法。
• METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Charrier Jean-Damien

  公开号：US20120178926A1

  公开（公告）日：2012-07-12

  A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and claims, comprises the step of: a) cyclizing a compound represented by Structural Formula A: under suitable reductive cyclisation conditions to form a compound represented by Structural Formula B: wherein R 10 is LG 1 or —X 1 R 1 , and -LG 1 is a suitable leaving group; and b) optionally, when R 10 of Structural Formula (B) is LG 1 , further comprising the step of replacing the -LG 1 of Structural Formula (B) with —X 1 R 1 to form the compound represented by Structural Formula (I).

  一种制备结构式(I)所代表的化合物或其药学上可接受的盐的方法，其中结构式(I)的变量如说明书和权利要求书所述，包括以下步骤： a) 在适当的还原环化条件下，将结构式A所代表的化合物环化，形成结构式B所代表的化合物，其中R10为LG1或—X1R1，-LG1为适当的离去基团； b) 可选地，当结构式(B)的R10为LG1时，进一步包括将结构式(B)的-LG1替换为—X1R1，以形成结构式(I)所代表的化合物。
• TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：Charrier Jean-Damien

  公开号：US20120277425A1

  公开（公告）日：2012-11-01

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及作为蛋白激酶抑制剂有用的化合物。本发明还提供了包括上述化合物的药学上可接受的组合物以及使用组合物治疗各种疾病、状况或障碍的方法。本发明还提供了制备本发明化合物的方法。
• 4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PLK1 PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2010542B1

  公开（公告）日：2012-01-25
• US7763629B2
  申请人：——

  公开号：US7763629B2

  公开（公告）日：2010-07-27